News


IT | 2020-06-16
TurkNet renforce ses services internet haut débit grâce aux équipements 400G d’Ekinops

 

 

Lien vers le communiqué de presse



IT | 2020-05-26
Ekinops réussit son entrée sur le marché de l’Accès 10G

Lien vers le communiqué de presse

 



IT | 2020-05-18
Ekinops obtient une ligne de financement complémentaire de 12 M€ sous forme de prêt garanti par l’Etat

 

Lien vers le communiqué de presse



IT | 2020-05-11
La nouvelle plateforme OTN d’Ekinops sélectionnée par un client majeur pour décupler la capacité de son réseau

Lien vers le communiqué de presse



IT | 2020-04-24
Ekinops permet à CM’IN de renforcer ses services haut débit résidentiels et d'entreprise avec une infrastructure optique à 100G

 

Lien vers le communiqué de presse



Life Science | 2020-04-21
Annual General Meeting of Kuros Biosciences approves all resolutions


 

Schlieren (Zurich), Switzerland,April 21, 2020 – Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved all resolutions proposed by the Board of Directors.Two proposed resolutions relating to capital increases were not put up for voting.

 

The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and Consolidated Financial Statements for the year 2019 and took note of the Reports of the Auditors. Shareholders discharged the Board and the Executive Committee, voted in favor of the proposed appropriation of the Annual Results and approved the compensation for the members of the Board and the Executive Committee.

 

Clemens van Blitterswijk was re-elected as Chairman and Leanna Caron, Joost de Bruijn, Scott P. Bruder and Oliver Walker were re-elected as members of the Board. Mr. Walker and Mrs. Caron were re-elected as members of the Compensation Committee. The law firm Keller KLG, Zürich was elected as Independent Proxy. PricewaterhouseCoopers were confirmed for another one-year term as the Company’s auditor.

 

The adjustment of the Authorized Share Capital (up to 2,588,665 registered shares with a nominal value of CHF 1.00 each) and of the Conditional Share Capital for Bonds and similar Debt Instruments (up to 2,588,665 registered shares with a nominal value of CHF 1.00 each) and the corresponding changes to the Articles of Incorporation were withdrawn.

 

The Annual General Meeting took place at the Company’s headquarters in Schlieren. Based on Article 6a of the COVID-19 Ordinance 2 of the Swiss Federal Council, the Company asked its shareholders to vote through the independent proxy. 8,027,979 shares or 35.7% of a total of 22'469'946 shares were represented. The Annual General Meeting was held without an audience.

 

 

For further information, please contact:

Kuros Biosciences AG

LifeSci Advisors

Michael Grau

Hans Herklots

Chief Financial Officer

Media & Investors

Tel +41 44 733 47 47

+41 79 598 7149

michael.grau@kurosbio.com

hherklots@lifesciadvisors.com

 

 

no responsibility for updating forward-looking statements or adapting them to future events or developments.

About Kuros Biosciences AG

Kuros Biosciences (SIX:KURN)  is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland, Bilthoven, The Netherlands and Burlington, MA, U.S. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.

 

About Fibrin-PTH

Fibrin-PTH (KUR-113) consists of a natural fibrin-based healing matrix with an immobilized targeted bone growth factor (truncated human parathyroid hormone (PTH) analog). Fibrin-PTH is designed to be applied directly into and around an intervertebral body fusion device as a gel, where it polymerizes in situ. Fibrin-PTH functions via the well-established mechanism of action of parathyroid hormone; has been demonstrated in animal models of spinal fusion to be comparable to rhBMP-2; and has been shown in preclinical studies to be easy to use and ideal for open or minimally invasive techniques. Fibrin PTH  is an investigational drug/biologic combination product candidate. Fibrin PTH  has been evaluated in animals for use in lumbar interbody fusion. The safety & efficacy of Fibrin PTH has not yet been evaluated for spinal fusion in humans.

 

About MagnetOs

MagnetOs bone graft has an advanced submicron surface topography that leads to the formation of bone, rather than scar tissue, following implantation. In preclinical models, MagnetOs preferentially directs early wound healing toward the bone-forming pathway, meaning that bone can be formed even in soft tissues without the need for added cells or growth factors, resulting in an osteoinductive claim in Europe. MagnetOs promotes local bone formation equivalent to current gold standard, autograft. A substantial number of clinically relevant and predictive studies have demonstrated its equivalence to the current gold standard (patient’s own bone, which may not be available in sufficient quantities and/or involves morbidity, costs and pain associated with its harvesting from another healthy site of the patient’s body). MagnetOs is now supported by over two years’ clinical experience since its launch in the United Kingdom in May 2017. For more information, see: www.magnetosbonegraft.com

 

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.



IT | 2020-04-08
Ekinops en croissance au 1er trimestre 2020 malgré les impacts de la pandémie

 

Lien vers le communiqué de presse



Life Science | 2020-03-26
Kuros Biosciences reports results for the full year 2019

Media Release (PDF)



Life Science | 2020-03-18
Kuros strengthens orthobiologics patent portfolio

  • Grant of US patent covering the use of PTH containing matrices for spinal fusion
  • Grant of US patent covering osteoinductive materials made by certain methods
  • Further strengthens Kuros’s position as a leader in the field of orthobiologics

 

Schlieren (Zurich), Switzerland, March 18, 2020 – Kuros Biosciences (SIX: KURN) today announced that its subsidiary, Kuros Biosurgery AG, has been granted the US patent, US 10’589’001, entitled ‘Pharmaceutical formulation for use in spinal fusion’.  This patent covers the use of parathyroid hormone (PTH) containing matrices for spinal fusion. 

 

The granting of this patent strengthens Kuros proprietary position on the use of PTH containing matrices in spinal fusion, the primary indication of Kuros’ Fibrin-PTH development program.

 

Kuros’s intellectual property portfolio in orthobiologics, its primary area of activity, has also been further strengthened by its Dutch subsidiary, Kuros Biosciences BV, recently being granted the US patent, US 10’561’683, entitled “Method for producing an osteoinductive calcium phosphate and products thus obtained” by the United States Patent and Trademark Office (USPTO).

 

This patent covers certain osteoinductive materials produced by Kuros’s proprietary production processes and further expands the patent portfolio relating to Kuros’s MagnetOs product line. The granting of this patent follows the granting, in the second half of last year, of other patents related to the MagnetOs product family, specifically, Japanese patent 6’559’665, and Australian patent 2016229595.

 

Joost de Bruijn, Chief Executive Officer of Kuros, said: “The granting of these patents both strengthens our position as a leader in this field and our ability to exploit that leadership for the benefit of our shareholders, our customers and their patients.”

 

 

For further information, please contact:

Kuros Biosciences AG

Media & Investors

Michael Grau

Hans Herklots

Chief Financial Officer

LifeSci Advisors

Tel +41 44 733 47 47

+41 79 598 7149

michael.grau@kurosbio.com

hherklots@lifesciadvisors.com

 

 

About Kuros Biosciences AG

Kuros Biosciences (SIX:KURN)  is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland, Bilthoven, The Netherlands and Burlington, MA, U.S. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.

 

About Fibrin-PTH

Fibrin-PTH (KUR-113) consists of a natural fibrin-based healing matrix with an immobilized targeted bone growth factor (truncated human parathyroid hormone (PTH) analog). Fibrin-PTH (KUR-113) is designed to be applied directly into and around an intervertebral body fusion device as a gel, where it polymerizes in situ. Fibrin-PTH (KUR-113) functions via the well-established mechanism of action of parathyroid hormone; has been demonstrated in animal models of spinal fusion to be comparable to rhBMP-2; and has been shown in preclinical studies to be easy to use and ideal for open or minimally invasive techniques. Fibrin PTH (KUR-113) is an investigational drug/biologic combination product candidate. Fibrin PTH (KUR-113) has been evaluated in animals for use in lumbar interbody fusion. The safety & efficacy of Fibrin PTH (KUR-113) has not yet been evaluated for spinal fusion in humans.

 

About MagnetOs

MagnetOs bone graft has an advanced submicron surface topography that leads to the formation of bone, rather than scar tissue, following implantation. In preclinical models, MagnetOs preferentially directs early wound healing toward the bone-forming pathway, meaning that bone can be formed even in soft tissues without the need for added cells or growth factors, resulting in an osteoinductive claim in Europe. MagnetOs promotes local bone formation equivalent to current gold standard, autograft. A substantial number of clinically relevant and predictive studies have demonstrated its equivalence to the current gold standard (patient’s own bone, which may not be available in sufficient quantities and/or involves morbidity, costs and pain associated with its harvesting from another healthy site of the patient’s body). MagnetOs is now supported by over two years’ clinical experience since its launch in the United Kingdom in May 2017. For more information, see: www.magnetosbonegraft.com

 

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.



IT | 2020-03-17
Ekinops annonce Compose, une nouvelle suite de produits logiciels, et lance SD-WAN Xpress

Lien vers le communiqué de presse



IT | 2020-02-26
Résultats annuels 2019 : Chiffre d’affaires +11% - EBITDA +43% Marge d’EBITDA record à 16,0%

Lien vers le communiqué de presse



IT | 2020-02-18
Orange Business Services choisit Dell Technologies et Ekinops pour les plateformes uCPE afin d'accélérer la transformation des réseaux Edge

Lien vers le communiqué de presse



IT | 2020-02-07
Renforcement du bilan de Paragon ID

Lien vers le communiqué



IT | 2020-02-04
L’opérateur américain United Fiber & Data déploie la solution FlexRate 600G d’Ekinops

Lien vers le communiqué de presse



IT | 2020-01-30
Progression de +17% du chiffre d’affaires au 2ème trimestre 2019/20, dont +7% de croissance organique

Lien vers le communiqué



Life Science | 2020-01-30
Kuros reports publication of MagnetOs preclinical data demonstrating superiority to market-leading synthetic bone grafts in spinal fusion

         Head-head study of spinal fusion versus the ‘best-in-class’ alternatives within category

         Accepted for publication in Clinical Spine Surgery – a surgeon focused journal

         Presented by leading academic expert at largest annual meeting of spine surgeons

Schlieren (Zurich), Switzerland, January 30, 2020 – Kuros Biosciences (SIX: KURN) today announced the publication of data from a clinically-relevant preclinical model comparing MagnetOs with autologous bone, Vitoss® BA2X (Stryker Corp.) and Novabone Putty® (Novabone Products, LLC) in instrumented posterolateral spinal fusion in sheep.

Utilizing multiple assessments for fusion, the study concluded that MagnetOs is an appropriate alternative to autograft when used as a standalone graft and was significantly better at achieving uniform, solid and stable fusions than the comparator products.

The publication, which is entitled "MagnetOs, Vitoss & Novabone in a multi-endpoint study of posterolateral fusion: A true fusion or not?”, has been accepted for publication by Clinical Spine Surgery and is available online as an open access paper via the following link:

https://journals.lww.com/jspinaldisorders/Abstract/publishahead/MagnetOs,_Vitoss,_and_Novabone_in_a_Multi_endpoint.99250.aspx

Joost de Bruijn, Chief Executive Officer of Kuros, said: “This robust and clinically-relevant large animal study confirms that MagnetOs really is different from other synthetic grafts on the market. Our early clinical feedback from leading spine surgeons is consistent with this dataset. Kuros has further committed to conducting at least ten post-market clinical studies to validate these encouraging outcomes.”

Professor Bill Walsh, University of New South Wales, Australia, who was principal investigator of the study and presented the data at this year’s North American Spine Society annual meeting in Chicago last September said: “I’ve investigated many of the leading synthetic bone grafts in this model and, in my experience, MagnetOs leads to the most compelling fusion outcomes of all the grafts I’ve tested.”

About the study

MagnetOs Putty was implanted stand-alone and compared to autograft bone, Vitoss BA2X and Novabone Putty. Female Merino sheep underwent posterolateral fusion at L2-3 and L4-5 levels with instrumentation. After 12 weeks, outcomes were evaluated by manual palpation, range of motion testing, micro-computed tomography, histology and histomorphometry. Fusion assessment by manual palpation 12 weeks after implantation revealed 100% fusion rates for MagnetOs Putty and autograft treated levels, whilst the fusion rate for the comparator materials was 33% for each group. No significant differences in range of motion were observed between MagnetOs Putty and autograft. Treated segments were significantly less rigid in Vitoss BA2X treated segments (Lateral bending & flexion-extension) and Novabone Putty treated segments (Lateral bending). The fusion rate, when measured through histology, was 83%, 75%, 0% and 0% respectively for MagnetOs Putty, autograft, Vitoss BA2X and Novabone Putty. There was significantly more bone (Histomorphometry) and significantly greater fusion mass (MicroCT) for MagnetOs Putty compared to Vitoss BA2X and Novabone Putty.

 

For further information, please contact:

Kuros Biosciences AG     Media & Investors

Michael Grau     Hans Herklots

Chief Financial Officer    LifeSci Advisors

Tel +41 44 733 47 47    +41 79 598 7149

michael.grau@kurosbio.com

hherklots@lifesciadvisors.com

 

About Kuros Biosciences AG

Kuros Biosciences (SIX:KURN)  is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland, Bilthoven, The Netherlands and Burlington, MA, U.S. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.

 

About MagnetOs

MagnetOs bone graft has an advanced submicron surface topography that leads to the formation of bone, rather than scar tissue, following implantation. In preclinical models, MagnetOs preferentially directs early wound healing toward the bone-forming pathway, meaning that bone can be formed even in soft tissues without the need for added cells or growth factors, resulting in an osteoinductive claim in Europe. MagnetOs promotes local bone formation equivalent to current gold standard, autograft. A substantial number of clinically relevant and predictive studies have demonstrated its equivalence to the current gold standard (patient’s own bone, which may not be available in sufficient quantities and/or involves morbidity, costs and pain associated with its harvesting from another healthy site of the patient’s body). MagnetOs is now supported by over two years’ clinical experience since its launch in the United Kingdom in May 2017. For more information, see: www.magnetosbonegraft.com

 

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.



IT | 2020-01-15
Ekinops rejoint le consortium OPEN ROADM

Lien vers le communiqué de presse



IT | 2020-01-09
Ekinops : 93,5 M€ de chiffre d’affaires en 2019 en progression soutenue de +11%, dont +21% au 4 ème trimestre

Lien vers le communiqué de presse


Last News

2020-06-16
TurkNet renforce ses services internet haut débit grâce aux équipements 400G d’Ekinops

2020-05-26
Ekinops réussit son entrée sur le marché de l’Accès 10G

2020-05-18
Ekinops obtient une ligne de financement complémentaire de 12 M€ sous forme de prêt garanti par l’Etat

2020-05-11
La nouvelle plateforme OTN d’Ekinops sélectionnée par un client majeur pour décupler la capacité de son réseau

2020-04-24
Ekinops permet à CM’IN de renforcer ses services haut débit résidentiels et d'entreprise avec une infrastructure optique à 100G

2020-04-21
Annual General Meeting of Kuros Biosciences approves all resolutions

2020-04-08
Ekinops en croissance au 1er trimestre 2020 malgré les impacts de la pandémie

2020-03-26
Kuros Biosciences reports results for the full year 2019

2020-03-18
Kuros strengthens orthobiologics patent portfolio

2020-03-17
Ekinops annonce Compose, une nouvelle suite de produits logiciels, et lance SD-WAN Xpress

2020-02-26
Résultats annuels 2019 : Chiffre d’affaires +11% - EBITDA +43% Marge d’EBITDA record à 16,0%

2020-02-18
Orange Business Services choisit Dell Technologies et Ekinops pour les plateformes uCPE afin d'accélérer la transformation des réseaux Edge

2020-02-07
Renforcement du bilan de Paragon ID

2020-02-04
L’opérateur américain United Fiber & Data déploie la solution FlexRate 600G d’Ekinops

2020-01-30
Progression de +17% du chiffre d’affaires au 2ème trimestre 2019/20, dont +7% de croissance organique

2020-01-30
Kuros reports publication of MagnetOs preclinical data demonstrating superiority to market-leading synthetic bone grafts in spinal fusion

2020-01-15
Ekinops rejoint le consortium OPEN ROADM

2020-01-09
Ekinops : 93,5 M€ de chiffre d’affaires en 2019 en progression soutenue de +11%, dont +21% au 4 ème trimestre
 
Legal informationrealisation digitalcube